<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        35-93-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LINZESS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINACLOTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        290
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        204.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Forest Laboratories Ireland Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Forest Laboratories Ireland Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Allergan Inc
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A06AX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LINZESS is a prescription medicine used in adults to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritable bowel syndrome with constipation (IBS-C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a type of constipation called chronic idiopathic constipation (CIC). &ldquo;Idiopathic&rdquo; means the cause of the constipation is unknown.</p><p>&nbsp;</p><p><strong>How LINZESS works </strong></p><p><strong>&nbsp;</strong></p><p>LINZESS acts locally in your gut, helping you to feel less pain and less bloated, and to restore the normal functioning of your bowels. It is not absorbed into the body but attaches to receptor called guanylate cyclase C on the surface of your gut. By attaching to this receptor, it blocks the sensation of pain and allows liquid to enter from the body into the gut, thereby loosening the stools and increasing your bowel movements.</p><p>&nbsp;</p><p><strong>It is not known if LINZESS is safe and effective in children less than 18 years of age. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use linzess:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to linaclotide or any of the other ingredients of this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children less than 2 years of age.<strong> </strong>LINZESS can cause severe diarrhoea and your child could get severe dehydration (loss of a large amount of body water and salt).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your doctor know that you have a bowel blockage (intestinal obstruction).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p><strong>Before you take LINZESS, tell your doctor about your medical conditions, including if you: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. It is not known if LINZESS will harm your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if LINZESS passes into your breast milk. Talk with your doctor about the best way to feed your baby if you take LINZESS.</p><p>&nbsp;</p><p>Your doctor has given this medicine to you after excluding other diseases, especially of your bowels and concluding that you suffer from IBS with constipation. Because these other diseases may have the same symptoms as IBS, it is important that you report any change or irregularity in symptoms to your doctor promptly<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Diarrhoea </strong></p><p>Severe diarrhoea associated with dizziness, fainting, low blood pressure (hypotension) and electrolyte abnormalities (low potassium level (hypokalemia) and low sodium level (hyponatremia)) requiring hospitalization or intravenous fluid administration have been reported in patients treated with LINZESS.</p><p><strong>If you experience severe or prolonged diarrhoea (passing of frequent watery stools for 7 days or more), stop taking LINZESS and contact your doctor (see section 4). Make sure you drink plenty of fluids to replace the water and electrolytes like potassium lost from the diarrhoea.</strong><strong>&nbsp; </strong></p><p><strong>&nbsp;</strong>Talk to your doctor if you experience bleeding from the bowel or rectum.</p><p><strong>&nbsp;</strong>Take special care if you are older than 65 years, as there is a higher risk of you experiencing diarrhoea<strong>. </strong></p><p><strong>&nbsp;</strong>Take also special care if you have severe or prolonged diarrhoea and an additional disease, such as high blood pressure, previous disease of the heart and blood vessels (e.g. such as previous heart attacks) or diabetes<strong>. </strong></p><p><strong>&nbsp;</strong>Talk to your doctor if you suffer from inflammatory diseases of the gut such as Crohn&rsquo;s disease or ulcerative colitis as LINZESS is not recommended in these patients.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tell your doctor about all the medicines you take, </strong>including prescription and over-the-counter medicines, vitamins and herbal supplements.<strong> </strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give LINZESS to children who are less than 2 years of age. &nbsp;</p><p>&nbsp;</p><p>LINZESS can cause severe diarrhoea and your child could get severe dehydration (loss of a large amount of body water and salt).</p><p>&nbsp;</p><p>&nbsp;</p><p>You should not give LINZESS to children 2 years to less than 18 years of age. It is not known if LINZESS is safe and effective in children less than 18 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and LINZESS</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:</p><p>Some medicines may not work as effectively if you have severe or prolonged diarrhoea, such as:</p><p>- Oral contraceptives. If you have very bad diarrhoea, the contraceptive pill may not work properly and the use of an extra method of contraception is recommended. See the instructions in the patient leaflet of the contraceptive pill you are taking</p><p>- &nbsp;Medicines that need careful and exact dosing, such as levothyroxine (a hormone to treat reduced function of the thyroid gland).</p><p>&nbsp;</p><p>Some medicines may increase the risk of diarrhoea when taken with LINZESS, such as:</p><p>- Medicines to treat stomach ulcers or excessive production of stomach acid called Proton Pump Inhibitors.</p><p>- Medicines to treat pain and inflammation called NSAIDs.</p><p>- Laxatives</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Linzess with food</strong></p><p>Adults who cannot swallow LINZESS capsules whole may open the LINZESS capsule and sprinkle the LINZESS beads over applesauce or mix LINZESS with bottle water before swallowing. It is not known if LINZESS is safe and effective when sprinkled on other foods or mixed with other liquids. &nbsp;LINZESS produces more frequent bowel movements and diarrhoea (looser stools) when it is taken with food than when it is taken on an empty stomach.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>Limited information is available on the effects of Linzess in pregnant and breast-feeding women.</p><p>&nbsp;</p><p>Do not take this medicine if you are pregnant, think you may be pregnant or are planning to have a baby,unless your doctor advises you to do so.</p><p>&nbsp;</p><p>In a milk-only lactation study in seven lactating women, who were already taking linaclotide therapeutically, neither linaclotide nor its active metabolite were detected in the milk. Therefore breastfeeding is not expected to result in exposure of the infant to linaclotide and Linzess can be used during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Linaclotide has no influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LINZESS exactly as your doctor tells you to take it. If you have not experienced improvement in your symptoms after 4 weeks of treatment, you should contact your doctor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LINZESS 1 time each day on an empty stomach, at least 30 minutes before your first meal of the day. You should also wait 30 minutes before eating a meal if you take LINZESS with applesauce or mixed with water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose, skip the missed dose. Just take the next dose at your regular time. Do not take 2 doses at the same time. LINZESS capsules should be swallowed whole. Do not crush or chew LINZESS.</p><p>o&nbsp; Adults who cannot swallow LINZESS capsules whole may open the LINZESS capsule and sprinkle the LINZESS beads over applesauce or mix LINZESS with bottled water before swallowing.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more LINZESS than you should</strong></p><p>&nbsp;The most likely effect of taking too much LINZESS is diarrhoea. Contact your doctor or pharmacist if you have taken too much of this medicine.</p><p>&nbsp;</p><p><strong>If you stop taking LINZESS</strong></p><p>It is preferable to discuss stopping treatment with your doctor before actually doing so.&nbsp; However, treatment with LINZESS can be safely stopped at any time.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Taking LINZESS in applesauce: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place 1 teaspoon of room temperature applesauce into a clean container. Open the LINZESS capsule and sprinkle all of the LINZESS beads onto the applesauce.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow all of the LINZESS beads and applesauce right away. Do not keep the applesauce for later use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not chew the LINZESS beads.</p><p>&nbsp;</p><p><strong>Taking LINZESS in water: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pour 1 ounce (30 mL) of room temperature bottled water into a clean cup. Open the LINZESS capsule and sprinkle all of the LINZESS beads into the cup of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the beads and water for at least 20 seconds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow all of the LINZESS beads and water mixture right away. Do not keep the mixture for later use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you see any LINZESS beads left in the cup, add another 1 ounce (30mL) of water to the beads in the cup, swirl for at least 20 seconds, and swallow right away.</p><p>&nbsp;</p><p><strong>Taking LINZESS in a nasogastric or gastrostomy feeding tube: </strong></p><p>Gather the supplies you will need to take your LINZESS dose. Your doctor should tell you what size catheter tipped syringe you will need for your dose. Ask your doctor if you have any questions about how to give LINZESS the right way.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the LINZESS capsule and pour all of the LINZESS beads into a clean container with 1 ounce (30 mL) of room temperature bottled water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the beads and water for at least 20 seconds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the plunger from the catheter tipped syringe, and then pour the LINZESS bead and water mixture into the syringe and replace the plunger.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the cap from the syringe, insert the tip of the syringe into the nasogastric or gastric feeding tube and push the plunger all the way in to give the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you see any LINZESS beads left in the container, add another 1 ounce (30 mL) of water to the beads in the container and repeat the process.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After giving the LINZESS dose, flush the nasogastric or gastrostomy tube with at least 10 mL of water.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong><u>Irritable Bowel Syndrome with Constipation (IBS-C)</u></strong></p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&nbsp;</p><p><strong>Diarrhoea is the most common side effect of LINZESS, and it can sometimes be severe. </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea often begins within the first 2 weeks of LINZESS treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea is normally short lived; however, if you experience severe or prolonged diarrhoea (passing frequent or watery stools for 7 days or more) and feel lightheaded, dizzy or faint, <strong>stop taking LINZESS and contact your doctor</strong>.</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach or abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;feeling bloated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach flu (viral gastroenteritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn/acid reflux (Gastroesophagal Reflux Disease)</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> <strong>(may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of control over passing stools (fecal incontinence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urgency to pass stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling lightheaded after standing up quickly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease appetite</p><p>&nbsp;</p><p><strong><u>Chronic Idiopathic Constipation (CIC) </u></strong></p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&nbsp;</p><p><strong>Diarrhoea is the most common side effect of LINZESS, and it can sometimes be severe. </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea often begins within the first 2 weeks of LINZESS treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea is normally short lived; however, if you experience severe or prolonged diarrhoea (passing frequent or watery stools for 7 days or more) and feel lightheaded, dizzy or faint, <strong>stop taking LINZESS and contact your doctor.</strong></p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach or abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling bloated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinusitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach flu (viral gastroenteritis)</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> <strong>(may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of control over passing stools (fecal incontinence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urgency to pass stools</p><p>Call your doctor or go to the nearest hospital emergency room right away, if you develop unusual or severe stomach-area (abdomen) pain, especially if you also have bright red, bloody stools or black stools that look like tar.</p><p>&nbsp;</p><p><u>Reporting side effects</u></p><p>If any of the side effects get serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist. You can also report side effects directly via national reporting system listed in section 6.&nbsp; By reporting side effects you can help provide more information on the safety of the medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial label and the carton after EXP:. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&ordm;C.</p><p>Keep Linzess in the original container. Do not subdivide or repackage. Protect from moisture.</p><p>Do not remove desiccant from the container. Keep bottles tightly closed in a dry place.</p><p>&nbsp;</p><p>Do not use this medicine if you notice any signs of damage to the bottle or any change in the appearance of the capsules.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What LINZESS contains </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is<strong> </strong><strong>linaclotide. </strong>Each capsule contains 145 or 290 micrograms of linaclotide.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: calcium chloride dihydrate, hypromellose, L-leucine, and microcrystalline cellulose. Capsule shell: gelatin and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                145 mcg: White to off-white opaque hard gelatin capsules with gray imprint "FL 145" 

290 mcg: White to off-white opaque hard gelatin capsules with gray imprint "FL 290" 

The product is supplied in high-density polyethylene (HDPE) bottle with silica gel desiccant and closed with aluminum heat induction sealed child-resistant polypropylene (PP) cap.

Pack size: Bottle of 30 capsules

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Forest Laboratories Ireland, Limited</p><p>Clonshaugh Business and Technology Park</p><p>Clonshaugh, Dublin 17, Ireland</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder and </strong></p><p>Allergan Inc.</p><p>2525 Dupont Drive</p><p>Irvine</p><p>United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in  08/2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لنزيس هو دواء يوصف للبالغين ويُستخدَم لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;متلازمة القولون العصبي المصحوبة بإمساك (IBS-C).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أحد أنواع الإمساك ويُطلق عليه إمساك مزمن مجهول السبب (CIC). المقصود بعبارة &quot;مجهول السبب&quot; أن أسباب الإمساك غير معروفة.</p><p dir="RTL">&nbsp;</p><p><strong>كيف يعمل</strong><strong> لنزيس</strong><strong> </strong></p><p dir="RTL">يعمل لنزيس موضعياً في أمعائك ، مما يساعدك على الشعور بألم أقل و انتفاخ أقل ، واستعادة الأداء الطبيعي لأمعائك. لا يتم امتصاصه في الجسم ، لكنه يرتبط مع مستقبلات تسمى جوانيليت سايكليز سي على سطح الأمعاء. من خلال الارتباط مع هذه المستقبلات ، فإنه يمنع الإحساس بالألم ويسمح للسائل بالدخول من الجسم إلى الأمعاء ، وبالتالي تخفيف البراز .وزيادة حركة الأمعاء الخاصة بك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>لم يثبت حتى الآن إذا كان لنزيس آمناً على الأطفال الذين تقل أعمارهم عن 18 عاماً أم لا.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول لنزيس في الحالات التالية:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك حساسية لليناكلوتايد او اًي من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للأطفال الأقل من سنتين<strong>.</strong> يسبب هذا الدواء إسهالاً شديداً، مما قد يؤدي إلى إصابة الطفل بجفاف شديد (بسبب فقدان الجسم لكمية كبيرة من المياه والأملاح).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنتَ تعرف أنت أو طبيبك أنكَ تعاني من انسداد في الأمعاء (انسداد معوي).</p><p><em>&nbsp;</em></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الاحتياطات والتحذيرات:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اطلبي النصيحة من الطبيب أو الممرضة قبل تناول هذا الدواء، إذا كنتِ:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;حاملاً أو تخططين للحمل. فلم يثبت حتى الآن ما إذا كان هذا الدواء سيلحق الضرر بالجنين أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في فترة الرضاعة الطبيعية أو تخططين لإرضاع طفلك طبيعياً. فلم يثبت حتى الآن ما إذا كان لينزيس يترسب في حليب الأم أم لا. تحدثي إلى طبيبكِ عن أفضل الوسائل لتغذية طفلكِ إذا كنتِ تتناولين لينزيس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>لقد وصف لك &nbsp;الطبيب هذا الدواء بعد استبعاد الأمراض الأخرى ، وخاصةً الأمعاء ، وخلص إلى أنك تعاني من متلازمة القولون العصبي المصحوبة بإمساك. نظراً لأن هذه الأمراض الأخرى قد يكون لها نفس الأعراض مثل متلازمة القولون العصبي ، فمن المهم أن تبلغ طبيبك بأي تغيير أو عدم انتظام في الأعراض على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>الإسهال</strong></p><p dir="RTL">تم الإبلاغ عن حالات لمرضى أُصيبوا -عند استخدامهم لينزيس في العلاج- بإسهال شديد مصحوب بدوخة وانخفاض ضغط الدم وتشوهات ناتجة عن انخفاض مستوى البوتاسيوم (نقص بوتاسيوم الدم) وانخفاض مستوى الصوديوم (نقص صوديوم الدم)، مما استدعى دخولهم المستشفى أو تناولهم محاليل عبر الأوردة.&nbsp;&nbsp;</p><p>&nbsp;</p><p>إذا كنت تعاني من الإسهال الحاد أو المطول (مرور البراز المائي المتكرر لمدة 7 أيام أو أكثر) ، فتوقف عن تناول لنزيس واتصل بطبيبك (انظر القسم 4). &nbsp;تأكد من شرب الكثير من السوائل لتحل محل الماء و الشوارد مثل البوتاسيوم المفقودة بسبب الإسهال.</p><p>&nbsp;</p><p>تحدث إلى طبيبك إذا كنت تعاني من نزيف من الأمعاء أو المستقيم.</p><p>&nbsp;</p><p>احذر بشكل خاص إذا كان عمرك أكبر من 65 عامًا ، فهناك خطر أكبر في أن تصاب بالإسهال.</p><p>&nbsp;</p><p>احذر أيضًا إذا كنت تعاني من الإسهال الحاد أو المطول و مرض إضافي ، مثل ارتفاع ضغط الدم ، أو مرض سابق في القلب والأوعية الدموية (مثل الأزمات القلبية السابقة) أو مرض السكري.</p><p>&nbsp;</p><p>تحدث إلى طبيبك إذا كنت تعاني من أمراض التهابية في الأمعاء مثل مرض كرون أو التهاب القولون التقرحي لأن لنزيس لا ينصح في استخدامه لهؤلاء المرضى.</p><p>&nbsp;</p><p><strong>أخبر طبيبك بجميع الأدوية التي تتناولها</strong>، بما في ذلك الأدوية الموصوفة أو المتاحة دون وصفة أو الفيتامينات أو المكملات الغذائية الغنية بالأعشاب.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يحظر إعطاء هذا الدواء للأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL">قد يُسبب لنزيس إسهال شديد يؤدي إلى إصابة طفلك بحالة خطيرة من الجفاف (فقدان كميات كبيرة من المياه والأملاح الموجودة بالجسم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ان لا يعطى لنزيس &nbsp;للأطفال من سنتين إلى أقل من 18 عامًا ، من غير المعروف ما إذا كان لنزيس آمن وفعال في الأطفال الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى</strong></p><p dir="RTL">أخبِر الطبيب أو الصيدلي إذا كنتَ تتناول أو قد تناولت مؤخراً أو ربما تتناول أي أدوية أخرى.</p><p dir="RTL"><strong></strong>&nbsp; قد لا تعمل بعض الأدوية بشكل فعال إذا كنت تعاني من الإسهال الحاد أو المطول ، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ادوية منع الحمل التي تؤخذ عن طريق الفم. إذا كنت تعاني من إسهال شديد ، فقد لا تعمل حبوب منع الحمل بشكل صحيح</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويوصى باستخدام وسيلة إضافية لمنع الحمل. انظر التعليمات في نشرة المريض لحبوب منع الحمل التي تتناولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتاج إلى حذر و جرعات دقيقة، مثل ليفوثيروكسين (هرمون يعالج انخفاض وظيفة الغدة درقية).</p><p dir="RTL"><strong></strong>&nbsp; قد تزيد بعض الأدوية من خطر الإصابة بالإسهال عند تناولها مع لنزيس ، مثل:</p><p>&nbsp;&nbsp;&nbsp; الأدوية لعلاج قرحة المعدة أو الإنتاج المفرط لحمض المعدة يسمى مثبطات مضخة البروتون.<strong>- </strong></p><p dir="RTL">-&nbsp;&nbsp; الأدوية لعلاج الألم والالتهابات تسمى مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">-&nbsp;&nbsp; الملينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعل مع الأغذية</strong></p><p dir="RTL">فيما يتعلق بالبالغين الذين يتعذر عليهم ابتلاع كبسولة لينزيس كاملةً، يمكنهم فتح الكبسولة وتفريغ محتوياتها في صوص التفاح أو زجاجة مياه. لم يثبت حتى الآن مدى درجة أمان هذا الدواء وفاعليته عند إضافته إلى الطعام أو مزجه بسوائل أخرى.</p><p>لنزيس ينتج حركة الأمعاء والإسهال بشكل متكرر (براز اكثر رخاوة) عند تناوله مع الغذاء اكثر من عند تناوله على معدة فارغة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتوفر سوى معلومات محدودة عن مدى تأثير لنزيس على السيدات الحوامل والمرضعات.</p><p>&nbsp;</p><p dir="RTL">احذري تناول لنزيس إذا كنتِ في فترة الحمل أو تعتقدين أنكِ حامل أو تخططين للحمل أو كنتِ في فترة الرضاعة الطبيعية،</p><p>&nbsp;</p><p dir="RTL">إلا إذا نصحكِ الطبيب بتناول هذا الدواء.</p><p><strong>&nbsp;</strong></p><p>في دراسة عن الرضاعة فقط أجريت على سبع نساء مرضعات ، واللواتي كن يتناولن ليناكلوتيد بالفعل ، لم يتم اكتشاف ليناكلوتيد ولا مستقلبه النشط في الحليب. لذلك لا يُتوقع أن تؤدي الرضاعة الطبيعية إلى تعرض الرضيع لليناكلوتيد ويمكن استخدام لينزيس أثناء الرضاعة الطبيعية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">لا يؤثر ليناكلوتيد في قدرتك على القيادة وتشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تناول لنزيس حسب وصف الطبيب. إذا لم تشعر بتحسن في الأعراض بعد 4 أسابيع من العلاج ، فيجب عليك الاتصال بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الجرعة الموصى بها هي كبسولة واحدة يومياً على معدة فارغة، قبل أول وجبة في اليوم بـ 30 دقيقة على الأقل. يجب أيضاً أن تنتظر 30 دقيقة قبل تناول الطعام إذا كنتَ تأخذ جرعتك من لنزيس مع صوص التفاح أو الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا فاتتك إحدى الجرعات، فلا تعوضها. خذ جرعتك التالية في وقتها المعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يجب ابتلاع كبسولة لنزيس كاملةً. تجنب تفتيت كبسولة لنزيس أو مضغها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيما يتعلق بالبالغين الذين يتعذر عليهم ابتلاع كبسولة لنزيس كاملةً، يمكنهم فتح الكبسولة وتفريغ محتوياتها في صوص التفاح أو المياه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذا تناولت لنزيس اكثر </strong><strong>مما يجب</strong></p><p>التأثير الأكثر ترجيحًا لتناول الكثير من لنزيس هو الإسهال. اتصل بطبيبك أو الصيدلي إذا كنت قد تناولت الكثير من هذا الدواء.</p><p>&nbsp;</p><p><strong>اذا توقفت عن تناول لنزيس</strong></p><p dir="RTL">من الأفضل مناقشة وقف العلاج مع طبيبك قبل القيام بذلك بالفعل. ومع ذلك، يمكن ايقاف العلاج باستخدام لنزيس بأمان في أي وقت.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;إضافة لنزيس إلى صوص التفاح:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تضاف ملعقة واحدة من صوص التفاح بدرجة حرارة الغرفة إلى إناء نظيف. افتح كبسولة لنزيس وأضف جميع محتوياتها إلى صوص التفاح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تناول صوص التفاح المضاف إليه محتويات كبسولة لنزيس على الفور، دون أن تؤجل تناوله لوقتٍ لاحق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تجنب مضغ محتويات كبسولة لنزيس.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;إضافة لنزيس إلى الماء:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أحضر كأساً نظيفاً وصب فيه أوقية واحدة (30 مل) من مياه معدنية بدرجة حرارة الغرفة. افتح كبسولة لنزيس وأضف محتوياتها إلى كأس الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لإذابة محتوى الكبسولة في الماء، قم بالتقليب لمدة 20 ثانية على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اشرب الماء المضاف إليه محتويات كبسولة لنزيس على الفور، دون أن تؤجل ذلك لوقتٍ لاحق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في حال ترسب بعض محتويات كبسولة لنزيس في الكأس، أضف أوقية أخرى من المياه المعدنية (30 مل) إلى المحتوى المترسب مع التقليب لمدة لا تقل عن 20 ثانية ثم ابتلعها على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;أخذ دواء لنزيس من خلال أنبوب التغذية الذي يصل من الفم إلى المعدة أو عبر جدار البطن:</strong></p><p dir="RTL">&nbsp;جهِّز اللوازم التي تحتاج إليها استعداداً لتناول جرعة لنزيس. يتعين على الطبيب أن يخبرك بالمقاس المناسب لإبرة القسطرة التي تحتاج إليها لأخذ جرعتك. إذا كان لديك أي سؤال عن الطريقة الصحيحة لأخذ لنزيس، فاستشر طبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;افتح كبسولة لنزيس وأفرغ محتوياتها في إناء نظيف يحتوي على أوقية واحدة (30 مل) من مياه معدنية بدرجة حرارة الغرفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لإذابة محتوى الكبسولة في الماء، قم بالتقليب لمدة 20 ثانية على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل المكبس من إبرة القسطرة، ثم ضع الماء المذاب فيه محتويات كبسولة لنزيس في الإبرة واستبدل المكبس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;استبعد غطاء الإبرة، وأدخِل طرفها في الأنبوبة التي تصل من الفم إلى المعدة أو عبر جدار البطن، ثم ادفع المكبس إلى الداخل لإعطاء الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في حال ترسب بعض محتويات كبسولة لنزيس في الإناء، أضف أوقية أخرى من الماء (30 مل) إلى المحتوى المترسب في الإناء وكرر العملية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بعد إعطاء جرعة لنزيس، ادفع الماء إلى الأنبوبة التي تمر من الفم إلى المعدة أو عبر جدار البطن بكمية لا تقل عن 10 مل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يسبب هذا الدواء بعض الآثار الجانبية، ولكن ليس بالضرورة أن تظهر على جميع الأشخاص.</p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فاستشر الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة.</p><p>&nbsp;</p><p dir="RTL"><strong><u>متلازمة القولون العصبي المصحوبة بإمساك (</u></strong><strong><u>IBS-C</u></strong><strong><u>)</u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً</strong> (قد تؤثر في أكثر من 1 من بين كل 10 أشخاص<strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإسهال من الآثار الجانبية الأكثر شيوعاً عند تناول لينزيس، وقد يتطور في بعض الأحيان إلى إسهال شديد.</strong></p><ul><li dir="RTL">غالباً يبدأ الإسهال خلال أول أسبوعين من فترة العلاج بدواء لينزيس.</li><li dir="RTL">عادة ما يكون الإسهال لمدة قصيرة. ومع ذلك ، إذا كنت تعاني من الإسهال الحاد أو الطويل ( خروج البراز بشكل متكرر أو مائي لمدة 7 أيام أو أكثر) وتشعر بالدوار أو الدوخة أو الإغماء ، <strong>توقف عن تناول لنزيس واتصل بطبيبك</strong>.</li></ul><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;آثار جانبية شائعة</strong> (قد تؤثر في شخص واحد أو أكثر من بين كل 10 شخص):</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة أو البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الشعور بالانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنفلونزا المعدة (التهاب المعدة والأمعاء الفيروسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في المعدة/ارتجاع الحمض (مرض ارتجاع المريء المعدي)</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong><strong> (</strong>قد تؤثر في شخص واحد أو أكثر من بين كل 100 شخص):</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التحكم عند خروج البراز (سلس البراز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة المستمرة إلى إخراج البراز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار بعد الوقوف بسرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>إمساك مزمن مجهول السبب (</u></strong><strong><u>CIC</u></strong><strong><u>)</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً</strong> (قد تؤثر في أكثر من 1 من بين كل 10 أشخاص<strong>)</strong></p><ul><li dir="RTL">&nbsp;الإسهال</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإسهال من الآثار الجانبية الأكثر شيوعاً عند تناول لينزيس، وقد يتطور في بعض الأحيان إلى إسهال شديد.</strong></p><ul><li dir="RTL">غالباً يبدأ الإسهال خلال أول أسبوعين من فترة العلاج بدواء لينزيس.</li><li dir="RTL">عادة ما يكون الإسهال لمدة قصيرة. ومع ذلك ، إذا كنت تعاني من الإسهال الحاد أو الطويل ( خروج البراز بشكل متكرر أو مائي لمدة 7 أيام أو أكثر) وتشعر بالدوار أو الدوخة أو الإغماء ، <strong>توقف عن تناول لنزيس واتصل بطبيبك</strong>.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر في شخص واحد أو أكثر من بين كل 10 شخص):</p><ul><li dir="RTL">ألم المعدة أو البطن</li><li dir="RTL">الشعور بالانتفاخ</li><li dir="RTL">ريح</li><li dir="RTL">التهاب الجهاز التنفسي العلوي</li><li dir="RTL">التهاب الجيوب الأنفية</li><li dir="RTL">عسر الهضم</li><li dir="RTL">إنفلونزا المعدة (التهاب المعدة والأمعاء الفيروسي)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة (</strong>قد تؤثر في شخص واحد أو أكثر من بين كل 100 شخص):</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التحكم عند خروج البراز (سلس البراز)</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;الحاجة المستمرة إلى إخراج البراز</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الإبلاغ عن حدوث أي آثار جانبية</u></p><p><u>&nbsp;</u></p><p dir="RTL">إذا تطور أي من هذه الآثار الجانبية لدرجة خطيرة، أو إذا لاحظت حدوث أي آثار جانبية غير واردة بهذه النشرة، فأخبر الطبيب أو الصيدلي. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرة من خلال نظام الإبلاغ الوطني المذكور في القسم 6. &nbsp;إن الإبلاغ عن الآثار الجانبية من شأنه المساعدة من خلال توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول الأطفال ومرمى أبصارهم.</p><p><strong>&nbsp;</strong></p><p dir="RTL">لا يستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على الشريط والعلبة بعد كلمة EXP:. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;احتفظ بالدواء في عبوته الأصلية. لا تقسمه على عبوات ولا تعيد تجميعه وتعبئته. احتفظ به بعيداً عن الرطوبة.</p><p dir="RTL">احتفظ بالكيس المجفف المزيل للرطوبة في العبوة. احتفظ بالعبوة محكمة الغلق وفي مكان جاف.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظتَ أي علامات واضحة تشير إلى تلف العبوة، أو أي تغير في شكل الكبسولات.</p><p>&nbsp;</p><p dir="RTL">لا ينبغي التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. سل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. تساعد هذه التدابير في حماية البيئة.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات لنزيس</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;المادة الفعَّالة هي <strong>ليناكلوتيد</strong>. تحتوي كل كبسولة على 145 أو 290 ملجم من ليناكلوتيد.</p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوريد الكالسيوم ثنائي الهيدرات، هيدروكسي بروبيل ميثيل سيللوز، ل&ndash;ليوسين، سليولوز دقيق التبلور الطبقة الخارجية للكبسولة: الجيلاتين وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">145 ميكروجراماً: كبسولات صلبة من الجيلاتين لونها أبيض أو يميل إلى الأبيض ومطبوع عليها بلون رمادي &quot;FL 145&quot;.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;290 ميكروجراماً: كبسولات صلبة من الجيلاتين لونها أبيض أو يميل إلى الأبيض ومطبوع عليها بلون رمادي &quot;FL 290&quot;.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;تأتي الكبسولات في عبوة مصنوعة من مادة البولي إثيلين العالية الكثافة ومزودة بكيس مجفف لإزالة الرطوبة يحتوي على هلام السيليكا ومحكمة الغلق بغطاء من الألومنيوم المعالج حرارياً المصنوع من البولي بروبلين، لكي يصعب على الأطفال العبث به.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: عبوة تحتوي على 30 كبسولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة فورست لابوراتوريز أيرلاندا، ليمتد</p><p dir="RTL">كلونشوغ بيزنيس آند تكنولوجي بارك</p><p dir="RTL">كلونشوغ، دبلن 17، أيرلندا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المالكة لحق التسويق </strong></p><p dir="RTL">&nbsp;شركة أليرجان العالمية للصناعات الدوائية المحدودة،</p><p dir="RTL">2525 دوبونت درايف</p><p dir="RTL">إرفاين</p><p dir="RTL">الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في 8/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LINZESS (linaclotide) 145 mcg capsules.
LINZESS (linaclotide) 290 mcg capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
145mcg: Each capsule contains 145 micrograms of linaclotide
290mcg: Each capsule contains 290 micrograms of linaclotide.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

145mcg: White to off-white opaque hard gelatin capsules with gray imprint "FL 145" 
290mcg: White to off-white opaque hard gelatin capsules with gray imprint "FL 290" 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linzess is a guanylate cyclase-C agonist indicated in adults for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritable bowel syndrome with constipation (IBS-C)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic idiopathic constipation (CIC)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;The recommended dosage in adults is:</p><p>&bull; <u>Irritable Bowel Syndrome with Constipation (IBS-C):</u></p><p>&nbsp;&nbsp; The recommended dosage of LINZESS is 290 mcg orally once daily.</p><p>&nbsp;</p><p>&bull; <u>Chronic Idiopathic Constipation (CIC)</u>:</p><p>&nbsp; The recommended dosage of LINZESS is 145 mcg orally once daily.</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em><u>Elderly patients:</u></em></p><p>Clinical studies of LINZESS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.</p><p>&nbsp;</p><p><em><u>Pediatric population:</u></em></p><p>LINZESS is contraindicated in patients less than 2 years of age.</p><p>&nbsp;</p><p>Avoid use of LINZESS in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established (see Special Warnings and Precautions for use)(see Pediatric Use).</p><p><em>&nbsp;</em></p><p><em>Renal and Hepatic impairment:</em></p><p>Renal or hepatic impairment is not expected to affect the clearance of linaclotide or the active metabolite because linaclotide metabolism occurs within the gastrointestinal tract and plasma concentrations are not measurable following administration of the recommended dosage.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><strong>Preparation and Administration Instructions </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LINZESS on an empty stomach, at least 30 minutes prior to the first meal of the day</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the same time.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not crush or chew LINZESS capsule or capsule contents.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow LINZESS capsule whole.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For adult patients with swallowing difficulties, LINZESS capsules can be opened and administered orally in either applesauce or with water or administered with water via a nasogastric or gastrostomy tube. Sprinkling of LINZESS beads on other soft foods or in other liquids has not been tested.</p><p>&nbsp;</p><p><u>Oral Administration in Applesauce: </u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place one teaspoonful of room-temperature applesauce into a clean container.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the capsule.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sprinkle the entire contents (beads) on applesauce.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consume the entire contents immediately. Do not chew the beads. Do not store the bead-applesauce mixture for later use.</p><p>&nbsp;</p><p><u>Oral Administration in Water: </u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pour approximately 30 mL of room-temperature bottled water into a clean cup.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the capsule</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sprinkle the entire contents (beads) into the water</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl beads and water for at least 20 seconds.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the entire mixture of beads and water immediately.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add another 30 mL of water to any beads remaining in cup, swirl for 20 seconds, and swallow immediately.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store the bead-water mixture for later use.</p><p>&nbsp;</p><p>Note: The drug is coated on the surface of the beads and will dissolve off the beads into the water. The beads will remain visible and will not dissolve. Therefore, it is not necessary to consume all the beads to deliver the complete dose.</p><p>&nbsp;</p><p><u>Administration with Water via a Nasogastric or Gastrostomy Tube: </u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the capsule and empty the beads into a clean container with 30 mL of room-temperature bottled water.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mix by gently swirling beads for at least 20 seconds</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Draw-up the beads and water mixture into an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 seconds) to dispense the syringe contents into the tube.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add another 30 mL of water to any beads remaining in the container and repeat the process</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After administering the bead-water mixture, flush nasogastric/ gastrostomy tube with a minimum of 10 mL of water.</p><p>&nbsp;</p><p>Note: It is not necessary to flush all the beads through to deliver the complete dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LINZESS is contraindicated in: 
•	Patients with hypersensitivity to linaclotide or to any of the excipients listed in section 6.1
••	Patients less than 2 years of age due to the risk of serious dehydration (see Special Warnings and Precautions for use). 
•	Patients with known or suspected mechanical gastrointestinal obstruction 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age</strong></p><p>LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration. Based on insufficient information regarding GC-C intestinal expression in children less than 2 years of age, these patients may have an increased risk of developing diarrhea and its potentially serious consequences.&nbsp;</p><p>Avoid use of LINZESS in pediatric patients 2 years to less than 18 years of age as the safety and effectiveness of LINZESS in patients less than 18 years of age have not been established.</p><p>&nbsp;</p><p><strong>Diarrhoea </strong></p><p>Patients should be aware of the possible occurrence of diarrhoea and lower gastrointestinal bleeding during treatment. Diarrhoea was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhoea was similar between the IBS-C and CIC populations. Severe diarrhoea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients</p><p>In post-marketing experience, severe diarrhoea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or intravenous fluid administration have been reported in patients treated with LINZESS.</p><p>Patients should be instructed to inform their physician if severe or prolonged diarrhoea or lower gastrointestinal bleeding occurs (see section 4.8).</p><p>Should prolonged (e.g. more than 1 week) or severe diarrhoea occur, medical advice should be sought and temporary discontinuation of linaclotide until diarrhoea episode is resolved may be considered. Additional caution should be exercised in patients who are prone to a disturbance of water or electrolyte balance (e.g. elderly, patients with cardiovascular (CV) diseases, diabetes, hypertension), and electrolyte control should be considered.</p><p>Linaclotide has not been studied in patients with chronic inflammatory conditions of the intestinal tract, such as Crohn&#39;s disease and ulcerative colitis; therefore it is not recommended to use Linaclotide in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No drug-drug interaction studies have been conducted with LINZESS. Systemic exposures of drug and active metabolite are negligible following oral administration.</p><p>Linaclotide does not interact with the cytochrome P450 enzyme system based on the results of in vitro studies. In addition, linaclotide does not interact with common efflux and uptake transporters (including the efflux transporter P-glycoprotein (P-gp)). Based on these <em>in vitro </em>data no drug-drug interactions through modulation of CYP enzymes or common transporters are anticipated.</p><p>Concomitant treatment with proton pump inhibitors, laxatives or NSAIDs may increase the risk of diarrhoea. Caution should be used when co-administering LINZESS with such medications.</p><p>In cases of severe or prolonged diarrhoea, absorption of other oral medicinal products may be affected. The efficacy of oral contraceptives may be reduced, and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception. Caution should be exercised when prescribing medicinal products absorbed in the intestinal tract with a narrow therapeutic index such as levothyroxine as their efficacy may be reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p><u>Risk Summary</u></p><p>Linaclotide and its active metabolite are negligibly absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. The available data on LINZESS use in pregnant women are not sufficient to inform any drug-associated risk for major birth defects and miscarriage. In animal developmental studies, no effects on embryo-fetal development were observed with oral administration of linaclotide in rats and rabbits during organogenesis at doses much higher than the maximum recommended human dosage. Severe maternal toxicity associated with effects on fetal morphology were observed in mice <em>[see Data]</em>.</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p>&nbsp;</p><p><u>Data </u></p><p>&nbsp;</p><p><em>Animal Data </em></p><p>The potential for linaclotide to cause harm to embryo-fetal development was studied in rats, rabbits and mice. In pregnant mice, oral dose levels of at least 40,000 mcg/kg/day given during organogenesis produced severe maternal toxicity including death, reduction of gravid uterine and fetal weights, and effects on fetal morphology. Oral doses of 5,000 mcg/kg/day did not produce maternal toxicity or any adverse effects on embryo-fetal development in mice. Oral administration of up to 100,000 mcg/kg/day in rats and 40,000 mcg/kg/day in rabbits during organogenesis produced no maternal toxicity and no effects on embryo-fetal development. Additionally, oral administration of up to 100,000 mcg/kg/day in rats during organogenesis through lactation produced no developmental abnormalities or effects on growth, learning and memory, or fertility in the offspring through maturation.</p><p>&nbsp;</p><p>The maximum recommended human dose is approximately 5 mcg/kg/day, based on a 60-kg body weight. Limited systemic exposure to linaclotide was achieved in animals during organogenesis (AUC = 40, 640, and 25 ng&bull;hr/mL in rats, rabbits, and mice, respectively, at the highest dose levels). Linaclotide and its active metabolite are not measurable in human plasma following administration of the recommended clinical dosages. Therefore, animal and human doses should not be compared directly for evaluating relative exposure.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>&nbsp;</p><p><u>Risk Summary </u></p><p>LINZESS is minimally absorbed following oral administration and neither linaclotide nor its active metabolite were detected in the milk of lactating women [see Data]. Therefore breastfeeding is not expected to result in exposure of the infant to LINZESS. The effects of linaclotide or its metabolite on milk production in lactating women have not been studied.</p><p>&nbsp;</p><p><u>Data </u></p><p>A pharmacokinetic study assessed the amount of linaclotide and its active metabolite in breast milk following multiple, once daily doses of oral linaclotide (72 &mu;g, 145 &mu;g, or 290 &mu;g) in seven lactating women receiving the drug therapeutically. The concentrations of linaclotide and its metabolite in breast milk were below the limits of quantitation (LoQ) (&lt;0.25 ng/mL and &lt;1.00 ng/mL, respectively) in all samples during the dosing interval. Therefore breastfeeding is not expected to result in exposure of linaclotide or its metabolite to the breastfed child.</p><p>&nbsp;</p><p><strong><u>Pediatric Use</u></strong></p><p>LINZESS is contraindicated in patients less than 2 years of age. Avoid use of LINZESS in patients 2 years to less than 18 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established (see Special Warnings and Precautions for use).</p><p>&nbsp;</p><p>In nonclinical studies, deaths occurred within 24 hours in neonatal mice (human age equivalent of approximately 0 to 28 days) following oral administration of linaclotide, as described below in Juvenile Animal Toxicity Data. Based on insufficient information regarding GC-C intestinal expression in children less than 2 years of age, these patients may have an increased risk of developing diarrhea and its potentially serious consequences.</p><p>&nbsp;</p><p><u>Juvenile Animal Toxicity Data </u></p><p>In toxicology studies in neonatal mice, oral administration of linaclotide at 10 mcg/kg/day caused deaths on post-natal day 7 (human age equivalent of approximately 0 to 28 days). These deaths were due to rapid and severe dehydration produced by significant fluid shifts into the intestinal lumen resulting from GC-C agonism in neonatal mice.</p><p>&nbsp;</p><p>Tolerability to linaclotide increases with age in juvenile mice. In 2-week-old mice, linaclotide was well tolerated at a dose of 50 mcg/kg/day, but deaths occurred after a single oral dose of 100 mcg/kg. In 3-week-old mice, linaclotide was well tolerated at 100 mcg/kg/day, but deaths occurred after a single oral dose of 600 mcg/kg.</p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Geriatric Use</u></strong></p><p>&nbsp;</p><p><u>Irritable Bowel Syndrome with Constipation (IBS-C)</u></p><p>Of 2219 IBS-C patients in the placebo-controlled clinical studies of LINZESS (1, 2, and 6) 154 (7%) were 65 years of age and over, while 34 (2%) were 75 years and over. Clinical studies of LINZESS did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Because of the higher risk of diarrhoea seen in the clinical trials (see section 4.8), special attention should be given to these patients and the treatment benefit-risk ratio should be carefully and periodically assessed.</p><p>&nbsp;</p><p><u>Chronic Idiopathic Constipation (CIC)</u></p><p>Of 2498 CIC patients in the placebo-controlled clinical studies of LINZESS (Trials 3, 4, and 5), 273 (11%) were 65 years of age and over, while 56 (2%) were 75 years and over. Clinical studies of LINZESS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. Because of the higher risk of diarrhoea seen in the clinical trials (see section 4.8), special attention should be given to these patients and the treatment benefit-risk ratio should be carefully and periodically assessed.</p><p>&nbsp;</p><p><strong><u>Fertility</u></strong></p><p>Linaclotide had no effect on fertility or reproductive function in male and female rats at oral doses of up to 100,000 mcg/kg/day.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linaclotide has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Trials Experience </strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Exposure in clinical development included approximately 2570, 2040, and 1220 patients with either IBS-C or CIC treated with LINZESS for 6 months or longer, 1 year or longer, and 18 months or longer, respectively (not mutually exclusive).</p><p>Demographic characteristics were comparable between treatment groups in all studies.</p><p>&nbsp;</p><p><u>Irritable Bowel Syndrome with Constipation (IBS-C)</u></p><p>The data described below reflect exposure to LINZESS 290mcg in the two placebo-controlled clinical trials involving 1605 adult patients with IBS-C (Trials 1 and 2). Patients were randomized to receive placebo or 290 mcg LINZESS once daily on an empty stomach for up to 26 weeks.</p><p><!--[if supportFields]><span style='font-family:"Times New Roman",serif;
color:black'><span style='mso-element:field-begin'></span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-spacerun:yes'> </span>REF _Ref521287716 \h </span><span
style='font-family:"Times New Roman",serif;color:black'><span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003500320031003200380037003700310036000000</w:data>
</xml><![endif]--><!--[if supportFields]><span style='font-family:"Times New Roman",serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--> provides the incidence of adverse reactions reported in IBS-C patients in the LINZESS treatment group and at an incidence that was greater than in the placebo group. Frequency categories include the following: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt; 1/1,000) and very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Ref521287716'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref521287716'><span style='color:windowtext'><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Ref521287716'></span><span style='mso-element:field-end'></span><![endif]-->: &nbsp;Tabulated Summary of Adverse Reactions in Two Placebo-Controlled Trials (1 and 2) in Patients with IBS-C</p><table border="1" cellspacing="0" cellpadding="0" style="width:360px"><tbody><tr><td><p><strong>MedDRA </strong></p><p><strong>system organ class</strong></p></td><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Unknown</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td>&nbsp;</td><td><p>Gastroenteritis viral</p></td><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Nervous system disorders</p></td><td>&nbsp;</td><td><p>Headache</p></td><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea</p></td><td><p>Abdominal pain<sup> b</sup></p><p>Flatulence</p><p>Abdominal distension</p><p>Vomiting</p><p>Gastroesophageal</p><p>reflux disease</p></td><td><p>Faecal incontinence</p><p>Defecation urgency</p><p>Lower gastrointestinal</p></td><td>&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Decreased appetite</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo</p><p><sup>b</sup>: &ldquo;Abdominal pain&rdquo; term includes abdominal pain, upper abdominal pain, and lower abdominal pain.</p><p>&nbsp;</p><p>An additional placebo-controlled trial was conducted in 614&nbsp; IBS-C patients randomized to placebo or LINZESS 290 mcg once daily on an empty stomach for 12 weeks (Trial 6).</p><p>In Trial 6, adverse reactions that occurred at a frequency of &ge; 2% in LINZESS-treated patients (n=306) and at a higher rate than placebo (n=308) were:</p><p>&bull; Diarrhoea (LINZESS 290 mcg 5%; placebo 2%)</p><p>&bull; Headache (LINZESS 290 mcg 3%; placebo 1%)</p><p><em>&nbsp;</em></p><p><em>Diarrhoea </em></p><p>Diarrhoea was the most commonly reported adverse reaction of the LINZESS-treated patients in the pooled IBS-C pivotal placebo-controlled trials. In these trials, 20% of LINZESS-treated patients reported diarrhoea compared to 3% of placebo-treated patients. Severe diarrhoea was reported in 2% of the LINZESS-treated patients versus less than 1% of the placebo-treated patients, and 5% of LINZESS-treated patients discontinued due to diarrhoea vs less than 1% of placebo-treated patients. The majority of reported cases of diarrhoea started within the first 2 weeks of LINZESS treatment. Elderly (&gt;65 years), hypertensive and diabetic patients reported diarrhoea more frequently as compared to the overall IBS-C population included in the clinical trials.</p><p>&nbsp;</p><p><em>Adverse Reactions Leading to Discontinuation </em></p><p>In placebo-controlled trials in patients with IBS-C, 9% of patients treated with LINZESS and 3% of patients treated with placebo discontinued prematurely due to adverse reactions. In the LINZESS treatment group, the most common reasons for discontinuation due to adverse reactions were diarrhoea (5%) and abdominal pain (1%). In comparison, less than 1% of patients in the placebo group withdrew due to diarrhoea or abdominal pain.</p><p><em>Adverse Reactions Leading to Dose Reductions </em></p><p>In the open-label, long-term trials, 2147 patients with IBS-C received 290 mcg of LINZESS daily for up to 18 months. In these trials, 29% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were diarrhoea or other GI adverse reactions.</p><p>&nbsp;</p><p><u>Chronic Idiopathic Constipation (CIC) </u></p><p>The data described below reflect exposure to LINZESS 145mcg in the two double-blind placebo-controlled clinical trials of 1275 adult patients with CIC. Patients were randomized to receive placebo or 145 mcg LINZESS or 290 mcg LINZESS once daily on an empty stomach, for at least 12 weeks.</p><p><!--[if supportFields]><span
style='font-family:"Times New Roman",serif;color:black'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref521287745 \h
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]-->Table&nbsp;2<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003500320031003200380037003700340035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span style='font-family:"Times New Roman",serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--> provides the incidence of adverse reactions reported in CIC patients in the 145 mcg LINZESS treatment group and at an incidence that was greater than in the placebo treatment group. Frequency categories include the following: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt; 1/1,000) and very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Ref521287745'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref521287745'><span style='color:windowtext'> SEQ Table \*
ARABIC </span></span><span style='mso-bookmark:_Ref521287745'><span
style='font-weight:normal;mso-bidi-font-style:normal'><span style='mso-element:
field-separator'></span></span></span><![endif]-->2<!--[if supportFields]><span
style='mso-bookmark:_Ref521287745'></span><span style='mso-element:field-end'></span><![endif]-->: &nbsp;Tabulated Summary of Adverse Reactions in Two Placebo-controlled Trials (3 and 4) in Patients with CIC</p><table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td><p><strong>MedDRA </strong></p><p><strong>system organ class</strong></p></td><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Unknown</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td>&nbsp;</td><td><p>Gastroenteritis viral</p><p>Upper respiratory tract infection</p><p>Sinusitis</p></td><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea</p></td><td><p>Abdominal pain</p><p>Flatulence</p><p>Abdominal distension</p><p>Dyspepsia</p></td><td><p>Faecal incontinence</p><p>Defecation urgency</p></td><td>&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Diarrhoea </em></p><p>This section summarizes information from Trials 3 and 4 (pooled) regarding diarrhoea, the most commonly reported adverse reaction reported in LINZESS-treated patients in CIC placebo-controlled studies. In all trials, the majority of reported cases of diarrhoea started within the first 2 weeks of LINZESS treatment. Severe diarrhoea was reported in 2% of the 145 mcg LINZESS-treated patients (Trials 3 and 4, and less than 1% of the placebo-treated patients (Trials 3 and 4). Elderly (&gt;65 years) and diabetic patients reported diarrhoea more frequently as compared to the overall CIC population included in the clinical trials.</p><p><em>Adverse Reactions Leading to Discontinuation </em></p><p>In placebo-controlled trials in patients with CIC, 8% (Trials 3 and 4) of patients treated with 145 mcg of LINZESS discontinued prematurely due to adverse reactions compared to less than 4% (Trials 3 and 4) of patients treated with placebo.</p><p>In patients treated with 145 mcg LINZESS, the most common reasons for discontinuation due to adverse reactions were diarrhoea (5% in Trials 3 and 4) and abdominal pain (1% in Trials 3 and 4). In comparison, less than 1% of patients in the placebo group withdrew due to diarrhoea or abdominal pain (Trials 3 and 4).</p><p>&nbsp;</p><p><em>Adverse Reactions Leading to Dose Reductions </em></p><p>In the open-label, long-term trials, 1129 patients with CIC received 290 mcg of LINZESS daily for up to 18 months. In these trials, 27% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were diarrhoea or other GI adverse reactions.</p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during post approval use of LINZESS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Allergic reactions, angioedema, rash (urticaria or hives)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Hematochezia, rectal hemorrhage, nausea</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>The national pharmacovigilance center and drug safety center (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: &nbsp;+966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at &nbsp;+966-11-20382222, Exts: 2353-2356-2317-2354-2334-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>www.sfda.gov.sa/npc</u></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single LINZESS doses of 2897 mcg were administered to 22 healthy subjects; the safety profile in these subjects was consistent with that in the overall LINZESS-treated population, with diarrhoea being the most commonly reported adverse reaction.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: A06AX04</p><p>LINZESS (linaclotide) is a guanylate cyclase-C (G-CC) agonist. Linaclotide is a 14-amino acid peptide with the following chemical name: L-cysteinyl-L-cysteinyl-L-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonyl-glycyl-L-cysteinyl-L-tyrosine, cyclic (1-6), (2-10), (5-13)-tris (disulfide).</p><p>The molecular formula of linaclotide is C59H79N15O21S6 and its molecular weight is 1526.8. The amino acid sequence for linaclotide is shown below:</p><p><img alt="" width="419" height="123" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Linaclotide is an amorphous, white to off-white powder. It is slightly soluble in water and aqueous sodium chloride (0.9%). LINZESS contains linaclotide-coated beads in hard gelatin capsules. LINZESS is available as 145 mcg and 290 mcg capsules for oral administration.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, linaclotide has been shown to both accelerate GI transit and reduce intestinal pain.</p><p>In an animal model of visceral pain, linaclotide reduced abdominal muscle contraction and decreased the activity of pain-sensing nerves by increasing extracellular cGMP.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>Food Effect </em></p><p>Taking LINZESS immediately after the high fat breakfast resulted in looser stools and a higher stool frequency compared with taking it in the fasted state <em>[see Dosage and Administration (2.1, 2.2)]</em>. In clinical trials, LINZESS was administered on an empty stomach, at least 30 minutes before breakfast.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><strong>Irritable Bowel Syndrome with Constipation (IBS-C)</strong></p><p>The efficacy of LINZESS for the management of symptoms of IBS-C was established in two double-blind, placebo-controlled, randomized, multicenter trials in adult patients (Trials 1 and 2). A total of 800 patients in Trial 1 and 804 patients in Trial 2 [overall mean age of 44 years (range 18 to 87 years), 90% female, 77% white, 19% black, and 12% Hispanic] received treatment with LINZESS 290 mcg or placebo once daily and were evaluated for efficacy. All patients met Rome II criteria for IBS and were required, during the 2-week baseline period, to meet the following criteria:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a mean abdominal pain score of at least 3 on a 0-to-10-point numeric rating scale</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less than 3 complete spontaneous bowel movements (CSBMs) per week [a CSBM is a spontaneous bowel movement (SBM) that is associated with a sense of complete evacuation; a SBM is a bowel movement occurring in the absence of laxative use], and</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less than or equal to 5 SBMs per week.</p><p>The trial designs were identical through the first 12 weeks, and thereafter differed only in that Trial 1 included a 4-week randomized withdrawal (RW) period, and Trial 2 continued for 14 additional weeks (total of 26 weeks) of double-blind treatment. During the trials, patients were allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to take laxatives, bismuth, prokinetic agents, or other drugs to treat IBS-C or chronic constipation.</p><p>Efficacy of LINZESS was assessed using overall responder analyses and change-from-baseline endpoints. Results for endpoints were based on information provided daily by patients in diaries.</p><p>The 4 primary efficacy responder endpoints were based on a patient being a weekly responder for either at least 9 out of the first 12 weeks of treatment or at least 6 out of the first 12 weeks of treatment. For the 9 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain, at least 3 CSBMs and an increase of at least 1 CSBM from baseline, all in the same week, for at least 9 out of the first 12 weeks of treatment. Each of the 2 components of the 9 out of 12 weeks combined responder endpoint, abdominal pain and CSBMs, was also a primary endpoint.</p><p>For the 6 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain and an increase of at least 1 CSBM from baseline, all in the same week, for at least 6 out of the first 12 weeks of treatment. To be considered a responder for this analysis, patients did not have to have at least 3 CSBMs per week.</p><p>The efficacy results for the 9 out of 12 weeks and the 6 out of 12 weeks responder endpoints are shown in Tables 3 and 4, respectively. In both trials, the proportion of patients who were responders to LINZESS 290 mcg was statistically significantly higher than with placebo.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span style='mso-bookmark:Table3'></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:Table3'><span
style='color:windowtext'><span style='mso-spacerun:yes'> </span>SEQ Table \*
ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->3<!--[if supportFields]><span
style='mso-bookmark:Table3'></span><span style='mso-element:field-end'></span><![endif]-->:&nbsp; Efficacy Responder Rates in the Two Placebo-controlled IBS-C Trials: at Least 9 Out of 12 Weeks</p><p><img alt="" width="615" height="311" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0" style="width:661px"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Table <!--[if supportFields]><span style='mso-bookmark:Table4'></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:Table4'><span
style='color:windowtext'><span style='mso-spacerun:yes'> </span>SEQ Table \*
ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->4<!--[if supportFields]><span
style='mso-bookmark:Table4'></span><span style='mso-element:field-end'></span><![endif]-->: Efficacy Responder Rates in the Two Placebo-controlled IBS-C Trials: at Least 6 Out of 12 Weeks</p><table border="0" cellspacing="0" cellpadding="0" style="width:639px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>&nbsp;<img alt="" width="615" height="322" src="data:image/png;base64,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" /></strong></p></td></tr></tbody></table><p>&nbsp;</p><p>In each trial, improvement from baseline in abdominal pain and CSBM frequency was seen over the first 12-weeks of the treatment periods.&nbsp; For change from baseline in the 11-point abdominal pain scale, LINZESS 290 mcg began to separate from placebo in the first week.&nbsp;</p><p>Maximum effects were seen at weeks 6 - 9 and were maintained until the end of the study.&nbsp; The mean treatment difference from placebo at week 12 was a decrease in pain score of approximately 1.0 point in both trials (using an 11-point scale). Maximum effect on CSBM frequency occurred within the first week, and for change from baseline in CSBM frequency at week 12, the difference between placebo and LINZESS was approximately 1.5 CSBMs per week in both trials.</p><p>In each trial, in addition to improvements in abdominal pain and CSBM frequency over the first 12 weeks of the treatment period, improvements were observed in the following when LINZESS was compared to placebo: SBM frequency [SBMs/week], stool consistency [as measured by the Bristol Stool Form Scale (BSFS)], and amount of straining with bowel movements [amount of time pushing or physical effort to pass stool].&nbsp;</p><p>During the 4-week randomized withdrawal period in Trial 1, patients who received LINZESS during the 12-week treatment period were re-randomized to receive placebo or continue treatment on LINZESS 290&nbsp;mcg. In LINZESS-treated patients re-randomized to placebo, CSBM frequency and abdominal-pain severity returned toward baseline within 1 week and did not result in worsening compared to baseline.&nbsp; Patients who continued on LINZESS maintained their response to therapy over the additional 4 weeks. Patients on placebo who were allocated to LINZESS had an increase in CSBM frequency and a decrease in abdominal pain levels that were similar to the levels observed in patients taking LINZESS during the treatment period.</p><p>&nbsp;</p><p><strong>Chronic Idiopathic Constipation (CIC) </strong></p><p>The efficacy of LINZESS for the management of symptoms of CIC was established in two double-blind, placebo-controlled, randomized, multicenter clinical trials in adult patients (Trials 3 and 4). A total of 642 patients in Trial 3 and 630 patients in Trial 4 [overall mean age of 48 years (range 18 to 85 years), 89% female, 76% white, 22% black, 10% Hispanic] received treatment with LINZESS 145 mcg, 290 mcg, or placebo once daily and were evaluated for efficacy. All patients met modified Rome II criteria for functional constipation. Modified Rome II criteria were less than 3 Spontaneous Bowel Movements (SBMs) per week and 1 of the following symptoms for at least 12 weeks, which need not be consecutive, in the preceding 12&nbsp;months:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straining during greater than 25% of bowel movements</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lumpy or hard stools during greater than 25% of bowel movements</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of incomplete evacuation during greater than 25% of bowel movements</p><p>Patients were also required to have less than 3 CSBMs per week and less than or equal to 6 SBMs per week during a 2-week baseline period. Patients were excluded if they met criteria for IBS-C or had fecal impaction that required emergency room treatment.</p><p>The trial designs were identical through the first 12 weeks. Trial 3 also included an additional 4-week randomized withdrawal (RW) period. During the trials, patients were allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to take laxatives, bismuth, prokinetic agents, or other drugs to treat chronic constipation.</p><p>The efficacy of LINZESS was assessed using a responder analysis and change-from-baseline endpoints. Results for endpoints were based on information provided daily by patients in diaries.&nbsp;</p><p>A CSBM responder in the CIC trials was defined as a patient who had at least 3 CSBMs and an increase of at least 1 CSBM from baseline in a given week for at least 9 weeks out of the 12-week treatment period. The CSBM responder rates are shown in <!--[if supportFields]><span
style='font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref521285605 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;5<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003500320031003200380035003600300035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span style='font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]-->. During the individual double-blind placebo-controlled trials, LINZESS 290 mcg did not consistently offer additional clinically meaningful treatment benefit over placebo than that observed with the LINZESS 145 mcg dose.&nbsp; Therefore, the 145 mcg dose is the recommended dose. Only the data for the approved 145 mcg dose of LINZESS are presented in <!--[if supportFields]><span
style='font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref521285605 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;5<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003500320031003200380035003600300035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span style='font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]-->.&nbsp;</p><p>In Trials 3 and 4, the proportion of patients who were CSBM responders was statistically significantly greater with the LINZESS 145 mcg dose than with placebo.&nbsp;</p><p>Table&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Ref521285605'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref521285605'><span style='color:windowtext'> SEQ Table \*
ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->5<!--[if supportFields]><span
style='mso-bookmark:_Ref521285605'></span><span style='mso-element:field-end'></span><![endif]-->:&nbsp; Efficacy Responder Rates in the Two Placebo-controlled CIC Trials: at Least 9 Out of 12&nbsp;Weeks</p><table border="0" cellspacing="0" cellpadding="0" style="width:655px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><img alt="" width="615" height="201" src="data:image/png;base64,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" /></p></td></tr></tbody></table><p>CSBM frequency reached maximum level during week 1 and was also demonstrated over the remainder of the 12-week treatment period in Trial 3 and Trial 4.&nbsp; For the mean change from baseline in CSBM frequency at week 12, the difference between placebo and LINZESS was approximately 1.5 CSBMs.&nbsp;</p><p>On average, patients who received LINZESS across the 2 trials had significantly greater improvements compared with patients receiving placebo in stool frequency (CSBMs/week and SBMs/week), and stool consistency (as measured by the BSFS).</p><p>In each trial, in addition to improvements in CSBM frequency over the first 12 weeks of the treatment period, improvements were observed in each of the following when LINZESS was compared to placebo: SBM frequency [SBMs/week], stool consistency [as measured by the BSFS], and amount of straining with bowel movements [amount of time pushing or physical effort to pass stool].&nbsp;</p><p>During the 4-week randomized withdrawal period in Trial 3, patients who received LINZESS during the 12-week treatment period were re-randomized to receive placebo or continue treatment on the same dose of LINZESS taken during the treatment period. In LINZESS treated patients re-randomized to placebo, CSBM and SBM frequency returned toward baseline within 1 week and did not result in worsening compared to baseline. Patients who continued on LINZESS maintained their response to therapy over the additional 4 weeks. Patients on placebo who were allocated to LINZESS had an increase in CSBM and SBM frequency similar to the levels observed in patients taking LINZESS during the treatment period.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In general, linaclotide is minimally detectable in plasma following therapeutic oral doses and</p><p>therefore, standard pharmacokinetic parameters cannot be calculated.</p><p>Following single doses of up to 966 micrograms and multiple doses up to 290 micrograms of linaclotide, there were no detectable plasma levels of parent compound or the active metabolite (des-tyrosine). When 2,897 micrograms was administered on day 8, following a 7-day course of 290 micrograms/day, linaclotide was detectable in only 2 of 18 subjects at concentrations just above the lower limit of quantification of 0.2 ng/ml (concentrations ranged from 0.212 to 0.735 ng/ml). In the two pivotal phase 3 studies in which patients were dosed with 290 micrograms of linaclotide once daily, linaclotide was only detected in 2 out of 162 patients approximately 2 h following the initial linaclotide dose (concentrations were 0.241 ng/ml to 0.239 ng/ml) and in none of the 162 patients after 4 weeks of treatment. The active metabolite was not detected in any of the 162 patients at any time point.</p><p>&nbsp;</p><p><em>Food Effect </em></p><p>Neither linaclotide nor its active metabolite were detected in the plasma following administration of LINZESS 290 mcg once daily for 7 days both in the fasted and fed state in healthy subjects.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>As linaclotide is rarely detectable in plasma following therapeutic doses, standard distribution studies have not been conducted. It is expected that linaclotide is negligibly or not systemically distributed.</p><p>&nbsp;</p><p><u>Biotransformation<em> </em></u></p><p>Linaclotide is metabolised locally within the gastrointestinal tract to its active primary metabolite, des-tyrosine. Both linaclotide and des-tyrosine active metabolite are reduced and enzymatically proteolyzed within the gastrointestinal tract to smaller peptides and naturally occurring amino acids.</p><p>The potential inhibitory activity of linaclotide and its active primary metabolite MM-419447 on the human efflux transporters BCRP, MRP2, MRP3, and MRP4 and the human uptake transporters OATP1B1, OATP1B3, OATP2B1, PEPT1 and OCTN1 was investigated in vitro. Results of this study showed that neither peptide is an inhibitor of the common efflux and uptake transporters studied at clinically relevant concentrations.</p><p>The effect of linaclotide and its metabolites to inhibit the common intestinal enzymes (CYP2C9 and CYP3A4) and liver enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4) or to induce liver enzymes (CYP1A2, 2B6, and 3A4/5) was investigated in vitro. Results of these studies showed that linaclotide and des-tyrosine metabolite are not inhibitors or inducers of the cytochrome P450 enzyme system.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Active peptide recovery in the stool samples of fed and fasted healthy subjects following administration of LINZESS 290 mcg once daily for seven days averaged about 5% (fasted) and about 3% (fed) and all of it as the active metabolite.</p><p>Following a single oral dose of 2,897 micrograms linaclotide on day 8, after a 7-day course of 290 micrograms/day in 18 healthy volunteers, approximately 3 to 5% of the dose was recovered in the faeces, virtually all of it as the des-tyrosine active metabolite.</p><p>&nbsp;</p><p><u>Age and gender</u><strong><u> </u></strong></p><p>Clinical studies to determine the impact of age and gender on the clinical pharmacokinetics of linaclotide have not been conducted because it is rarely detectable in plasma. Gender is not expected to have any impact on dosing. For age related information, please see sections 4.2., 4.4., and 4.8.</p><p>&nbsp;</p><p><u>Renal impairment</u><strong><u> </u></strong></p><p>LINZESS has not been studied in patients who have renal impairment. Linaclotide is rarely detectable in plasma, therefore, renal impairment would not be expected to affect clearance of the parent compound or its metabolite.</p><p>&nbsp;</p><p><u>Hepatic impairment</u><strong><u> </u></strong></p><p>LINZESS has not been studied in patients who have hepatic impairment. Linaclotide is rarely detectable in plasma and is not metabolised by liver cytochrome P450 enzymes, therefore, hepatic impairment would not be expected to affect the metabolism or clearance of the parent drug or its metabolite.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis </u></p><p>In 2-year carcinogenicity studies, linaclotide was not tumorigenic in rats at doses up to 3500 mcg/kg/day or in mice at doses up to 6000 mcg/kg/day. The maximum recommended human dose is approximately 5&nbsp;mcg/kg/day based on a 60-kg bodyweight. Limited systemic exposure to linaclotide and its active metabolite was achieved at the tested dose levels in animals, whereas no detectable exposure occurred in humans. Therefore, animal and human doses should not be compared directly for evaluating relative exposure.</p><p>&nbsp;</p><p><u>Mutagenesis </u></p><p>Linaclotide was not genotoxic in an <em>in vitro </em>bacterial reverse mutation (Ames) assay or in the <em>in vitro </em>chromosomal aberration assay in cultured human peripheral blood lymphocytes.</p><p>&nbsp;</p><p><u>Impairment of Fertility</u></p><p>Linaclotide had no effect on fertility or reproductive function in male and female rats at oral doses up to 100,000 mcg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The inactive ingredients of LINZESS 145 mcg and 290 mcg capsules include: calcium chloride dihydrate, hypromellose, L-leucine, and microcrystalline cellulose. The components of the capsule shell include gelatin and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p><p>Keep Linzess in the original container. Do not subdivide or repackage. Protect from moisture.</p><p>Do not remove desiccant from the container. Keep bottles tightly closed in a dry place.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product is supplied in high-density polyethylene (HDPE) bottle with silica gel desiccant and closed with aluminum heat induction sealed child-resistant polypropylene (PP) cap.</p><p>Pack size: 30 capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allergan Inc.
2525 Dupont Drive
Irvine
United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/21
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>